SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-004161
Filing Date
2022-03-18
Accepted
2022-03-18 16:14:12
Documents
14
Period of Report
2022-03-18
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K janx-20220318.htm   iXBRL 8-K 60347
2 EX-99.1 janx-ex99_1.htm EX-99.1 226373
3 GRAPHIC img201480580_0.jpg GRAPHIC 2925
  Complete submission text file 0000950170-22-004161.txt   429240

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT janx-20220318_pre.xml EX-101.PRE 11969
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT janx-20220318.xsd EX-101.SCH 2487
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT janx-20220318_lab.xml EX-101.LAB 14847
8 EXTRACTED XBRL INSTANCE DOCUMENT janx-20220318_htm.xml XML 5112
Mailing Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037
Business Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037 858-750-4700
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 22752687
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences